Q-omics provides the consensus-scored IGHV7-81 profile across patient tissues and cancer cell-line models. IGHV7-81 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHV7-81 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, IGHV7-81 RNA expression shows 12,617 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, LUAD, and KIRP as cancer lineages where IGHV7-81 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHV7-81 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHV7-81 survival associations across molecular data types. IGHV7-81 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHV7-81 RNA expression–survival associations across cancer types. High IGHV7-81 expression shows unfavorable associations in KIRP and DLBC, but favorable associations in HNSC, PAAD, BRCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHV7-81 RNA expression.
This table summarizes IGHV7-81 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGHV7-81. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHV7-81 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, ESCA, PAAD and BLCA. The LUAD box plot shows higher IGHV7-81 RNA expression in tumor versus normal tissue (log2 FC = +1.700, t-test p < 0.001).
This table shows molecular features associated with IGHV7-81 in patient tissues and cancer cell lines. In patient samples, IGHV7-81 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
